Posted by Michael Wonder on 29 Sep 2020
ICER to assess treatment for Alzheimer’s disease
29 September 2020 - Report will be subject of CTAF meeting in May 2021; open Input now being accepted until 16 October 2020.
The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of aducanumab (Biogen) for treatment of Alzheimer’s disease.
An FDA decision on aducanumab is expected in early 2021.
